Iodine I 131 tositumomab

Drug Profile

Iodine I 131 tositumomab

Alternative Names: 131-I-anti-B1 antibody; 131-I-tositumomab; Anti-CD20 murine monoclonal antibody-I-131; B1; Bexxar; I-131 anti-B1 antibody; Iodine 131 tositumomab; Iodine-131 anti-B1 antibody; Tositumomab; TST/I131-TST

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Corixa Corp
  • Developer GlaxoSmithKline
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Apoptosis stimulants; CD20 antigen inhibitors; Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Non-Hodgkin's lymphoma
  • Discontinued Mantle-cell lymphoma

Most Recent Events

  • 20 Feb 2014 Withdrawn for Non-Hodgkin's lymphoma (Refractory metastatic disease) in USA and Canada (IV)
  • 07 Aug 2013 GlaxoSmithKline announces intention to withdraw iodine I 131 tositumomab (Barrax®) from the market in USA and Canada on 20 February 2014
  • 01 Jun 2013 GlaxoSmithKline and Corixa complete a phase II clinical trial in Mantle cell lymphoma (first-line combination therapy) in USA (NCT00992992)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top